Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289962 · ClinicalTrials.gov registry record · Phase 1
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 273
- Enrollment target
NCT03289962 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 273 participants.
The verdict
NCT03289962, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 273 participants
- Enrollment target
Study Summary
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).
Interventions
- DRUG Atezolizumab
- DRUG Autogene cevumeran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289962
The ClinicalTrials.gov registry entry for NCT03289962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03289962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03289962 about?
NCT03289962 is a clinical study titled "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors". This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-...
What is the current status of trial NCT03289962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 273 participants. The study started on 2017-12-21. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT03289962?
The interventions under investigation include: Atezolizumab (DRUG), Autogene cevumeran (DRUG).
Who is sponsoring clinical trial NCT03289962?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.